Pernea, M;
Sutcliffe, AG;
(2016)
Clobazam and Its Use in Epilepsy.
Pediatric Reports
, 8
(2)
, Article 6516. 10.4081/pr.2016.6516.
Preview |
Text
sutcliffe_Clobazam and Its Use in Epilepsy.pdf Download (99kB) | Preview |
Abstract
Clobazam (CLB) is an older anti-epileptic drug, with a slightly different chemical structure from that of the classic benzodiazepines currently used in the treatment of epilepsy, which confers less sedative properties in terms of negative adverse effects. It is also thought to be better tolerated than other anti-epileptic drugs, whilst maintaining a very similar level of efficacy. It has been tested extensively in over 50 studies on more than 3000 patients with epilepsy and is now approved as an adjunctive treatment of epilepsy in >100 countries. The aim of this review is to evaluate several existing studies on the effectiveness of CLB as an adjunctive therapy in the treatment of epilepsy and whether this therapy is more useful in particular types of epilepsy or seizure prevention. This is not a systematic review but a general overview of some of the most recent studies on the effectiveness of CLB as an adjunctive therapy. Additionally, the benefits of having an oral suspension of CLB will be evaluated with regards to patient groups benefiting from this formulation. The last issue addressed is that of the importance of prescribing CLB by brand, along with the benefits and risks of not doing so.
| Type: | Article |
|---|---|
| Title: | Clobazam and Its Use in Epilepsy |
| Location: | Italy |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.4081/pr.2016.6516 |
| Publisher version: | http://doi.org/10.4081/pr.2016.6516 |
| Language: | English |
| Additional information: | © Copyright M. Pernea and A. G. Sutcliffe, 2016. Licensee PAGEPress, Italy. This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BYNC 4.0). The author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use. |
| Keywords: | Clobazam, adjunctive therapy, generic prescribing, oral suspension |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Population, Policy and Practice Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1509284 |
Archive Staff Only
 |
View Item |
